IM Cannabis (NASDAQ:IMCC) Stock Rating Cut to Strong Sell at Wall Street Zen

Wall Street Zen cut shares of IM Cannabis (NASDAQ:IMCC) to a strong sell rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of IM Cannabis in a report on Tuesday, July 21st. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

IM Cannabis Price Performance

IMCC opened at $1.58 on Friday. IM Cannabis has a 12 month low of $1.55 and a 12 month high of $77.10. The business has a 50-day moving average of $2.84 and a two-hundred day moving average of $6.02. The stock has a market capitalization of $331,800.00, a price-to-earnings ratio of -0.03 and a beta of 2.21.

IM Cannabis (NASDAQ:IMCC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter. The firm had revenue of $5.34 million for the quarter.

About IM Cannabis

IM Cannabis Corp. is a medical cannabis company focused on the cultivation, importation, distribution and sale of cannabis products. The company markets products under the IMC brand and serves patients through regulated medical cannabis channels.

IM Cannabis operates primarily in Israel and Germany. In Israel, the company’s activities include supplying medical cannabis products through pharmacies and other authorized distribution channels. In Germany, it participates in the medical cannabis market through the importation and distribution of pharmaceutical-grade products.

The company was established in 2018 and has developed its business through subsidiaries and strategic partnerships in its target markets.